User profiles for David R. Taft
David R. TaftLong Island University Verified email at liu.edu Cited by 949 |
Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations
Pregnancy is associated with numerous physiological changes that influence absorption,
distribution, metabolism and excretion. Moreover, the magnitude of these effects changes as …
distribution, metabolism and excretion. Moreover, the magnitude of these effects changes as …
The isolated perfused rat kidney model: a useful tool for drug discovery and development
DR Taft - Current Drug Discovery Technologies, 2004 - ingentaconnect.com
Over the past three decades, the Isolated Perfused Rat Kidney (IPK) has been used to study
numerous aspects of renal drug disposition. Among the available ex-vivo methods to study …
numerous aspects of renal drug disposition. Among the available ex-vivo methods to study …
[BOOK][B] Advanced drug formulation design to optimize therapeutic outcomes
RO Williams, DR Taft, JT McConville - 2007 - books.google.com
This title demonstrates how advanced formulation designs and delivery technologies can be
used to improve drug efficacy and treatment outcomes in particular therapeutic categories …
used to improve drug efficacy and treatment outcomes in particular therapeutic categories …
Radioprotective effects of ON 01210. Na upon oral administration
ON 01210.Na (Ex-RAD), a chlorobenzylsulfone derivative was investigated for its pharmacologic
and radioprotective properties when administered via oral and subcutaneous (SC) …
and radioprotective properties when administered via oral and subcutaneous (SC) …
Drug excretion
DR Taft - Pharmacology, 2009 - Elsevier
Publisher Summary This chapter offers a comprehensive summary of drug excretion,
presenting an overview of membrane transporters in terms of classification, nomenclature, and …
presenting an overview of membrane transporters in terms of classification, nomenclature, and …
Application of physiologically based pharmacokinetic‐pharmacodynamic modeling in preterm neonates to guide gentamicin dosing decisions and predict antibacterial …
…, K Abduljalil, J Cusumano, DR Taft - The Journal of …, 2021 - Wiley Online Library
Clinical studies in preterm neonates are rarely performed due to ethical concerns and difficulties
associated with trials and recruitment. Consequently, dose selection in this population …
associated with trials and recruitment. Consequently, dose selection in this population …
Preclinical drug development
As editors of the second edition of Preclinical Drug Development, we are pleased to present
this updated text on the science of safely moving therapeutic candidates into, and through, …
this updated text on the science of safely moving therapeutic candidates into, and through, …
Preclinical pharmacokinetics and in vitro activity of ON 01910. Na, a novel anti-cancer agent
AW Chun, SC Cosenza, DR Taft, M Maniar - Cancer chemotherapy and …, 2009 - Springer
Purpose ON 01910.Na is a novel targeted anti-cancer agent under clinical investigation in
Phase I and II trials. The purpose of this research was to evaluate the pharmacokinetic profile …
Phase I and II trials. The purpose of this research was to evaluate the pharmacokinetic profile …
Aristolochic acid I metabolism in the isolated perfused rat kidney
…, KG Dickman, T Freshwater, DR Taft… - Chemical Research …, 2012 - ACS Publications
Aristolochic acids are natural nitro-compounds found globally in the plant genus Aristolochia
that have been implicated in the severe illness in humans termed aristolochic acid …
that have been implicated in the severe illness in humans termed aristolochic acid …
Real-world experience with higher-than-recommended doses of lamivudine in patients with varying degrees of renal impairment
Background Although nucleoside reverse transcriptase inhibitors have been associated
with lactic acidosis, lamivudine (3TC) has not been reported to have an increased risk with …
with lactic acidosis, lamivudine (3TC) has not been reported to have an increased risk with …